Raymond James Financial Services Advisors’s Galmed Pharmaceuticals GLMD Stock Holding History

Raymond James Financial Services Advisors’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-19	Closed	-$11.9K	–	3280
2023 Q1	$11.9K	Hold	19	–	–	﹤0.01%	3214
2022 Q4	$13.9K	Sell	19 -21	-53%	-$11K	﹤0.01%	3178
2022 Q3	$18K	Sell	40 -5	-11%	-$3.41K	﹤0.01%	3171
2022 Q2	$42K	Buy	45 +1	+2%	+$1.33K	﹤0.01%	3102
2022 Q1	$101K	Buy	44 +27	+159%	+$61.2K	﹤0.01%	3113
2021 Q4	$45K	Buy	17 +2	+13%	+$7.22K	﹤0.01%	3198
2021 Q3	$59K	Buy	15 +3	+25%	+$12.6K	﹤0.01%	3172
2021 Q2	$51K	Hold	12	–	–	﹤0.01%	3207
2021 Q1	$59K	Buy	+12	New	+$66.4K	﹤0.01%	3087

Other funds holding GLMD

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TFGT

TS Financial Group (TSFG) Lake Forest, Illinois $794M AUM 24.65% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

BCM

Bourgeon Capital Management Darien, Connecticut $679M AUM 50.89% 1-Year Est. Return

Allworth Financial Folsom, California $23.6B AUM 20.99% 1-Year Est. Return

Raymond James Financial Services Advisors's GLMD Position: Q2 2023 in Review

Raymond James Financial Services Advisors sold out of Galmed Pharmaceuticals (GLMD) in Q2 2023, closing a stake of 19 shares — an estimated $11.9K sold.

Raymond James Financial Services Advisors first reported a position in GLMD in Q1 2021 and held it in 9 quarters. The position peaked at $101K in Q1 2022. 8 funds tracked by Wall St. Rank hold GLMD as of Q2 2023.

Raymond James Financial Services Advisors reported no remaining Galmed Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Raymond James Financial Services Advisors sold 19 Galmed Pharmaceuticals shares in Q2 2023, an estimated $11.9K.
Raymond James Financial Services Advisors first reported a position in Galmed Pharmaceuticals in Q1 2021 and held it in 9 quarters.
Raymond James Financial Services Advisors's Galmed Pharmaceuticals position peaked at $101K in Q1 2022.
8 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q2 2023.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2023, filed 25 Jul 2023.